Jens Hillengass is currently a Professor of Oncology and Internal Medicine and Chief of Myeloma at Roswell Park Comprehensive Cancer Center, Buffalo, NY, as well as being a Professor of Medicine at the University at Buffalo, Buffalo, NY.
Prof. Hillengass received his medical degree and PhD from the University of Heidelberg in Germany, as well as completing his fellowship in hematology and oncology there. He has also competed a further fellowship at the German Cancer Research Center in Heidelberg, Germany. Additionally, he is a member of the American Society of Hematology, International Myeloma Working Group, and the Black Swan Research Initiative.
Prof. Hillengass was previously the Head of the Autologous Transplant Program and the Deputy Head of the Multiple Myeloma Section at the University of Heidelberg, Germany.
Speaking on monoclonal plasma cell diseases
Prof. Hillengass has research experience in imaging hematological diseases, where his research group has established magnetic resonance imaging (MRI) and computed tomography (CT) as novel standard diagnostic techniques in multiple myeloma and its precursor diseases. He is also interested in myeloma bone disease, investigating the influence of physical activity on pain, quality of life and skeletal related events.
Additionally, Prof. Hillengass has been the Principal Investigator of several clinical trials, one of which assesses the safety of a BCMA antibody-drug conjugate (ADC) in patients with relapsed and refractory multiple myeloma, and another assessing the efficacy of abatacept, ixazomib citrate, and dexamethasone in treating chemotherapy-resistant multiple myeloma.